Not for release, publication or distribution, in whole or in part directly or
indirectly, in Australia, Canada, Japan or the United States (or any other
jurisdiction in which the release, publication or distribution would be
unlawful). This announcement does not constitute an offer of any of the
securities described herein.

Oslo, 29 April 2024: Reference is made to the stock exchange notice from Softox
Solutions AS (the "Company") 15. April 2024 regarding the commencement of the
subscription period in the subsequent offering of up to 125,000,000 new shares
(the "Subscription Period").

The Subscription Period ends today Monday 29 April 2024 at 16:30 hours (CEST).
Subscription rights that are not used to subscribe for Offer Shares before the
expiry of the Subscription Period will have no value and will lapse without
compensation to the holder.

Please see the Prospectus for more information about the subsequent offering.
The Prospectus, including subscription form, is electronically available at
www.soft-ox.com and www.sb1markets.no. 

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com